With over 30 years of academic experience in healthcare, Professor Dr. Evrim Metcalfe provides expert consultation, second opinions, and personalized treatment plans tailored specifically for you in managing your cancer treatment. Schedule your consultation today to benefit from leading and experienced expertise in the field.
Planning the most appropriate radiotherapy regimen based on your cancer diagnosis and staging, using the latest technology and evidence-based scientific protocols.
Re-evaluation of your diagnosis and treatment processes with current scientific support and multidisciplinary cancer team opinion.
Offering surgical-free cancer treatment opportunities for suitable cancer masses using advanced stereotactic technologies with high-standard precision radiotherapy.
Guidance in accessing scientific innovative treatment approaches in the field of cancer.
Simultaneous treatment management with specialists from every needed discipline for comprehensive cancer care at every stage of cancer.
Comprehensive and sustainable education about treatment options, side effects, and all types of supportive care throughout the cancer journey.
Department of Radiation Oncology, Istanbul Medipol University
Leading radiation oncology department with focus on advanced treatment techniques and patient care excellence.
Department of Radiation Oncology, Eskişehir Osmangazi University Faculty of Medicine, FMV Işık University MYO
Specialized in stereotactic radiosurgery and geriatric oncology through multi-center collaborations.
Department of Radiation Oncology, Eskişehir Osmangazi University Faculty of Medicine
Provided education to medical students and research assistants in clinical research and innovative radiotherapy technologies.
Radiation Oncology Clinic, Samsun Training and Research Hospital
Led clinic development as education and council coordinator during mandatory state service following specialist training.
Ege University Faculty of Medicine, Turkey
1998
Graduated with high honors achieving the Doctor of Medicine degree.
Dokuz Eylül University Faculty of Medicine, Turkey
2006
Successfully completed radiation oncology training and became a specialist.
St James' University Hospital, Leeds, UK
2012-2013
Participated in multidisciplinary head and neck cancer treatment team. Conducted scientific studies in head and neck cancer, lymphoma, and side effect clinics.
Some international articles by Professor Doctor Metcalfe:
Surface dose analysis and dosimetric comparison of Halcyon versus Truebeam in breast cancer radiotherapy: An OSL dosimetry study. J Appl Clin Med Phys, 2025; 26(6).
Evaluation of treatment outcomes and tolerability in older patients with rectal cancer treated with radiotherapy accompanied by the G-8 geriatric score: TROD13-003 multicenter study. Journal of Geriatric Oncology, 2024; 15(3).
Perspective of Turkish Medicine Students on Cancer, Cancer Treatments, Palliative Care, and Oncologists (ARES Study): a Study of the Palliative Care Working Committee of the Turkish Oncology Group (TOG). Journal of Cancer Education, 2020; 35(1).
CD105 (endoglin) expression as a prognostic marker of angiogenesis in squamous cell cervical cancer treated with radical radiotherapy. Journal of Cancer Research and Therapeutics, 2018; 14(6).
Multiple primary malignant neoplasms: A 10-year experience at a single institution from Turkey. Journal of Cancer Research and Therapeutics, 2017; 13(1).
Involved Node, Site, Field and Residual Volume Radiotherapy for Lymphoma: A Comparison of Organ at Risk Dosimetry and Second Malignancy Risks. Clinical Oncology, 2015; 27(7).
Timing of thoracic radiotherapy in limited stage small cell lung cancer: Results of early versus late irradiation from a single institution in Turkey. Asian Pacific Journal of Cancer Prevention, 2014; 15(15).
Comparison of hematologic toxicity between 3DCRT and IMRT planning in cervical cancer patients after concurrent chemoradiotherapy: A national multi-center study. European Journal of Gynaecological Oncology, 2014; 35(1).
Patterns of Failure after Intensity-modulated Radiotherapy in Head and Neck Squamous Cell Carcinoma using Compartmental Clinical Target Volume Delineation. Clinical Oncology, 2014; 26(10).
Dosimetric and Clinical Predictors of Acute Esophagitis in Lung Cancer Patients in Turkey Treated with Radiotherapy. Asian Pacific Journal of Cancer Prevention, 2013; 14(7).
Prognostic value of osteopontin in patients treated with primary radiotherapy for head and neck cancer. Asian Pacific Journal of Cancer Prevention, 2013; 14(9).
Comparing ultrasound with computerized tomography images to choose electron energy for radiotherapy boost field in breast cancer patients with breast conserving surgery. J BUON, 2010; 15(3).
Patient Demographics: 66-year-old male
Treatment Technique: Volumetric Arc Radiotherapy (VMAT)
Total Dose: 78 Gy in 39 fractions
Duration: 8 weeks
Excellent treatment tolerance with minimal side effects. PSA levels decreased significantly post-treatment. Patient reported improved quality of life and complete symptom resolution.
Patient Demographics: 59-year-old female
Treatment Technique: Single-fraction SRS
Total Dose: 18 Gy in 1 fraction
Duration: Single session
Patient who came from abroad for treatment and returned to her country within the same week achieved complete tumor response within 3 months. No neurological deficits observed. Patient maintained excellent cognitive function and returned to normal activities.
Patient Demographics: 61-year-old female
Treatment Technique: Hypofractionated IMRT
Total Dose: 42.5 Gy in 16 fractions
Duration: 3 weeks
Excellent cosmetic results with minimal acute toxicity achieved using visual guidance (VCD) and breath-hold system.
Patient Demographics: 62-year-old male
Treatment Technique: Stereotactic Body Radiation Therapy (SBRT)
Total Dose: 45 Gy in 5 fractions
Duration: 2 weeks
SBRT was safely completed with an every-other-day application schedule. Complete metabolic response was observed on PET CT scan after three months.
Patient details have been anonymized to protect privacy. All treatments were completed with informed consent and according to institutional protocols.
Your initial consultation will include a comprehensive review of your medical history, imaging studies, and pathology reports. Dr. Metcalfe will discuss treatment options, answer your questions, and develop a personalized treatment plan.
Treatment duration varies depending on the type and stage of cancer. Most patients receive daily treatments Monday through Friday for 1-8 weeks. Each treatment session typically lasts 15-30 minutes.
Side effects vary by treatment area and individual patient factors. Common side effects include fatigue and skin irritation. Dr. Metcalfe will discuss specific potential side effects based on your treatment plan.
We work with most major insurance providers. Please contact our office to verify coverage for your specific plan and treatment needs.
Absolutely. Second opinions are encouraged and can provide valuable perspective on your treatment options. Dr. Metcalfe regularly provides second opinion consultations for patients.
Yes, telehealth consultations are available for certain types of appointments, including some follow-ups and second opinion consultations. Please discuss this option when scheduling.
YouTube
Instagram
LinkedIn